Literature DB >> 27288203

Dynamics in insulin requirements and treatment safety.

R Harper1, R Donnelly1, Yixi Bi2, E Bashan3, R Minhas3, I Hodish4.   

Abstract

AIMS: The majority of insulin users have elevated HbA1c. There is growing recognition that the low success rates are due to variations in insulin requirements. Thus, frequent dosage adjustments are needed. In practice, adjustments occur sporadically due to limited provider availability. We investigated intra-individual dynamics of insulin requirements using data from a service evaluation of the d-Nav® Insulin Guidance Service. This service facilitates automated insulin dosage adjustments, as often as needed, to achieve and maintain optimal glycemic balance.
METHODS: Data were collected from subjects who have been using the service for more than a year. Events of considerable and persistent decrease in insulin requirements were identified by drops in total daily insulin ≥25%.
RESULTS: Overall, 62 patients were studied over an average period of 2.1±0.5 (mean±standard deviation) years. Stability in HbA1c was attained after ~3 quarters at 7.4%±0.2% (57.4mmol/mol±1mmol/mol). Events were identified in 56.5% of the patients. On average, each affected patient had 0.8±0.4 events per year, lasting 9.7±6.6weeks, while total daily insulin dosage decreased by 41.4±13.4%.
CONCLUSIONS: Our findings may call attention to a major contributing factor to hypoglycemia among insulin users. In reality, insulin dosage is seldom adjusted and thus transient periods of decrease in insulin requirements and overtreatment are usually overlooked.
Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Dosage; Hypoglycemia; Insulin requirements; Insulin therapy; Titration

Mesh:

Substances:

Year:  2016        PMID: 27288203     DOI: 10.1016/j.jdiacomp.2016.05.017

Source DB:  PubMed          Journal:  J Diabetes Complications        ISSN: 1056-8727            Impact factor:   2.852


  4 in total

1.  Automated insulin dosing guidance to optimise insulin management in patients with type 2 diabetes: a multicentre, randomised controlled trial.

Authors:  Richard M Bergenstal; Mary Johnson; Rebecca Passi; Anuj Bhargava; Natalie Young; Davida F Kruger; Eran Bashan; Stanley G Bisgaier; Deanna J Marriott Isaman; Israel Hodish
Journal:  Lancet       Date:  2019-02-23       Impact factor: 79.321

2.  The Bio-inspired Artificial Pancreas for Type 1 Diabetes Control in the Home: System Architecture and Preliminary Results.

Authors:  Pau Herrero; Mohamed El-Sharkawy; John Daniels; Narvada Jugnee; Chukwuma N Uduku; Monika Reddy; Nick Oliver; Pantelis Georgiou
Journal:  J Diabetes Sci Technol       Date:  2019-10-14

3.  Impact of a Novel Insulin Management Service on Non-insulin Pharmaceutical Expenses.

Authors:  John E Schneider; Anjani Parikh; Ivana Stojanovic
Journal:  J Health Econ Outcomes Res       Date:  2018-02-20

4.  Insulin therapy for type 2 diabetes - are we there yet? The d-Nav® story.

Authors:  I Hodish
Journal:  Clin Diabetes Endocrinol       Date:  2018-04-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.